Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Net Margin (2018 - 2025)

Historic Net Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 29.31%.

  • Dna X's Net Margin fell 125900.0% to 29.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.57%, marking a year-over-year decrease of 347300.0%. This contributed to the annual value of 58.83% for FY2024, which is 591800.0% down from last year.
  • Dna X's Net Margin amounted to 29.31% in Q3 2025, which was down 125900.0% from 66.8% recorded in Q2 2025.
  • Dna X's 5-year Net Margin high stood at 2.74% for Q1 2025, and its period low was 148.56% during Q4 2024.
  • Moreover, its 5-year median value for Net Margin was 29.31% (2025), whereas its average is 37.86%.
  • In the last 5 years, Dna X's Net Margin skyrocketed by 687900bps in 2022 and then tumbled by -1416500bps in 2024.
  • Quarter analysis of 5 years shows Dna X's Net Margin stood at 73.7% in 2021, then surged by 93bps to 4.91% in 2022, then plummeted by -41bps to 6.91% in 2023, then tumbled by -2050bps to 148.56% in 2024, then surged by 80bps to 29.31% in 2025.
  • Its Net Margin was 29.31% in Q3 2025, compared to 66.8% in Q2 2025 and 2.74% in Q1 2025.